WEBVTT

NOTE duration:"00:02:18.8160000"

NOTE recognizability:0.870

NOTE language:en-us

NOTE Confidence: 0.87011445

00:00:00.000 --> 00:00:01.870 Amario Snow Lima medical oncologist.

NOTE Confidence: 0.87011445

00:00:01.870 --> 00:00:04.689 I treat Melanoma and renal cell carcinoma.

NOTE Confidence: 0.87011445

00:00:04.690 --> 00:00:06.215 My major interest outside of

NOTE Confidence: 0.87011445

00:00:06.215 --> 00:00:08.179 these two diseases is really the

NOTE Confidence: 0.87011445

00:00:08.179 --> 00:00:09.719 development of immune therapies.

NOTE Confidence: 0.87011445

00:00:09.720 --> 00:00:11.616 I've been working on this probably

NOTE Confidence: 0.87011445

00:00:11.616 --> 00:00:14.332 for the past 35 years and it turns

NOTE Confidence: 0.87011445

00:00:14.332 --> 00:00:16.414 out that Melanoma and kidney cancer,

NOTE Confidence: 0.87011445

00:00:16.420 --> 00:00:19.100 which are the two diseases that are treat,

NOTE Confidence: 0.87011445

00:00:19.100 --> 00:00:21.438 are the most responsive to immune therapies,

NOTE Confidence: 0.87011445

00:00:21.440 --> 00:00:23.861 or at least there was a time when those

NOTE Confidence: 0.87011445

00:00:23.861 --> 00:00:26.361 were the only two diseases that were

NOTE Confidence: 0.87011445

00:00:26.361 --> 00:00:28.480 really responsive to immune therapies.

NOTE Confidence: 0.87011445

1

00:00:28.480 --> 00:00:30.598 With these new drugs that that.

NOTE Confidence: 0.87011445

00:00:30.600 --> 00:00:31.680 We helped develop.

NOTE Confidence: 0.87011445

00:00:31.680 --> 00:00:33.480 Immunotherapy is now used in

NOTE Confidence: 0.87011445

00:00:33.480 --> 00:00:35.160 almost every kind of cancer,

NOTE Confidence: 0.87011445

00:00:35.160 --> 00:00:37.446 but initially it was Melanoma and

NOTE Confidence: 0.87011445

00:00:37.446 --> 00:00:39.950 kidney cancer and that's why I was

NOTE Confidence: 0.87011445

00:00:39.950 --> 00:00:42.064 drawn to those two diseases and I've

NOTE Confidence: 0.87011445

00:00:42.138 --> 00:00:44.637 stayed with that for my entire career.

NOTE Confidence: 0.87011445

00:00:44.640 --> 00:00:46.044 We're very satisfied that

NOTE Confidence: 0.87011445

00:00:46.044 --> 00:00:47.812 approximately 50% of the patients

NOTE Confidence: 0.87011445

00:00:47.812 --> 00:00:49.582 can be really treated effectively

NOTE Confidence: 0.87011445

00:00:49.582 --> 00:00:52.009 with the medicines that we have now,

NOTE Confidence: 0.87011445

00:00:52.010 --> 00:00:53.414 but the truth is,

NOTE Confidence: 0.87011445

00:00:53.414 --> 00:00:55.990 the other 50% don't do well and can

NOTE Confidence: 0.87011445

00:00:55.990 --> 00:00:57.996 possibly die of their menist attic

NOTE Confidence: 0.87011445

00:00:57.996 --> 00:01:00.076 disease if not treated effectively.

00:01:00.080 --> 00:01:02.306 Research is really important in finding.

00:01:02.310 --> 00:01:04.222 A more effective treatments

00:01:04.222 --> 00:01:06.134 for those other 50%.

00:01:06.140 --> 00:01:08.138 So our clinical research is really

00:01:08.138 --> 00:01:09.888 focused around finding new medications

00:01:09.888 --> 00:01:11.688 that can effectively treat those

00:01:11.688 --> 00:01:13.797 that don't respond to the group

00:01:13.797 --> 00:01:15.317 of medications that work now,

00:01:15.320 --> 00:01:17.020 and we integrate our clinical

00:01:17.020 --> 00:01:18.720 research with our clinical practice.

00:01:18.720 --> 00:01:21.264 We feel that for the subset of patients

00:01:21.264 --> 00:01:23.816 that don't have viable standard of care,

00:01:23.820 --> 00:01:25.728 alternative options we should be offering

00:01:25.728 --> 00:01:27.422 them the best available investigational

00:01:27.422 --> 00:01:29.257 therapies that are out there.

00:01:29.260 --> 00:01:31.572 We take a very much a team approach

00:01:31.572 --> 00:01:33.764 to the treatment of our patients

00:01:33.764 --> 00:01:36.074 and we encourage people to ask

00:01:36.152 --> 00:01:38.462 questions and we try and spend as

00:01:38.462 --> 00:01:41.828 much time with them at the beginning.

00:01:41.830 --> 00:01:43.839 Of each patient journey at the at

00:01:43.839 --> 00:01:45.684 very first visit to answer all

00:01:45.684 --> 00:01:47.224 the questions that they have.

00:01:47.230 --> 00:01:49.406 But the other thing that we try and

00:01:49.406 --> 00:01:51.967 do is we try and answer the questions

00:01:51.967 --> 00:01:54.129 that they may not know to ask,

00:01:54.130 --> 00:01:56.326 so as much as possible we we try and

00:01:56.326 --> 00:01:58.521 have a very long conversation and I

00:01:58.521 --> 00:02:00.887 go through all aspects of the disease

00:02:00.887 --> 00:02:02.530 and Natural History, the treatment,

00:02:02.530 --> 00:02:04.030 how we monitor for recurrence.

NOTE Confidence: 0.87011445

00:02:04.030 --> 00:02:05.022 A number of visits.

NOTE Confidence: 0.87011445

00:02:05.022 --> 00:02:06.865 I also introduce them to our practice

NOTE Confidence: 0.87011445

00:02:06.865 --> 00:02:08.635 nurses which are in really important

NOTE Confidence: 0.87011445

00:02:08.635 --> 00:02:10.984 part of our practice because those that's

NOTE Confidence: 0.87011445

00:02:10.984 --> 00:02:13.096 the interface between the outside and.

NOTE Confidence: 0.87011445

00:02:13.100 --> 00:02:14.068 And into our clinic.